Literature DB >> 3216310

HIV infection among persons who inject illicit drugs: problems and prospects.

D C Des Jarlais1, S R Friedman.   

Abstract

Intravenous drug use continues as the second most common risk behavior associated with acquired immune deficiency syndrome (AIDS) in the United States and Europe. Recently there has been increased public and research attention to this problem. Five areas of public health concern for AIDS among i.v. drug users are identified and discussed: (a) the potential spread of human immunodeficiency virus (HIV) to drug users in developing countries; (b) the emergence of cocaine use associated with HIV infection; (c) ethnic differences in seroprevalence rates among i.v. drug users, with ethnic minorities tending to have higher rates; (d) difficulties in changing the sexual behavior of i.v. drug users; and (e) an increased frequency of fatal infections among HIV seropositive drug users that are not counted with the current surveillance definition of AIDS. There have been numerous studies of AIDS risk reduction among i.v. drug users, but the ultimate effect of the behavior change on spread of the virus is not yet clear. Preliminary studies from New York City, San Francisco, and Stockholm indicate a relative stabilization of seroprevalence in those cities, suggesting that the behavior changes reported in those cities may be significantly slowing the rate of viral spread.

Entities:  

Mesh:

Year:  1988        PMID: 3216310

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  11 in total

1.  Injection drug use among stimulant users in a national sample.

Authors:  Li-Tzy Wu; Daniel J Pilowsky; Wendee M Wechsberg; William E Schlenger
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

2.  History, ethics, and politics in AIDS prevention research.

Authors:  D C Des Jarlais; B Stepherson
Journal:  Am J Public Health       Date:  1991-11       Impact factor: 9.308

Review 3.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

4.  HIV seroprevalence among male IVDUs in Houston, Texas.

Authors:  M L Williams
Journal:  Am J Public Health       Date:  1990-12       Impact factor: 9.308

5.  HIV infection among women entering the New York State correctional system.

Authors:  P F Smith; J Mikl; B I Truman; L Lessner; J S Lehman; R W Stevens; E A Lord; R K Broaddus; D L Morse
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

6.  Demographic characteristics, risk behaviors, and HIV seroprevalence among intravenous drug users by site of contact: results from a community-wide HIV surveillance project.

Authors:  J McCusker; B Koblin; B F Lewis; J Sullivan
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

7.  Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA).

Authors:  Jessica L Reynolds; Supriya D Mahajan; Donald Sykes; Madhavan P N Nair
Journal:  Am J Infect Dis       Date:  2006

8.  Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection.

Authors:  A S Thompson; K M Blankenship; P A Selwyn; K Khoshnood; M Lopez; K Balacos; F L Altice
Journal:  J Community Health       Date:  1998-12

9.  Demography and the dual epidemics of tuberculosis and HIV: Analysis of cross-sectional data from Sub-Saharan Africa.

Authors:  Gambo Aliyu; Samer S El-Kamary; Alash'le Abimiku; William Blattner; Manhattan Charurat
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

10.  Heating Injection Drug Preparation Equipment Used for Opioid Injection May Reduce HIV Transmission Associated With Sharing Equipment.

Authors:  Laura J Ball; Colin Venner; Rommel G Tirona; Eric Arts; Kaveri Gupta; Joshua C Wiener; Sharon Koivu; Michael S Silverman
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.